GraphSeam - SCIB — Scibase Holding

Stay in touch

Footer

Original on investors.scibase.se

2026-10-14 SciBase secures first payer coverage with Highmark, marking a major commercial inflection point Bull 5 Bear 0 Order/contract

Oct 14 2026

SWEDEN - October 14, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in advanced technology for the detection and prevention of skin disease, announced today that Nevisense has received its first positive medical policy from Highmark Blue Cross Blue Shield, one of the largest Blue Cross Blue Shield organizations in the United States.

The decision marks a major milestone in SciBase's U.S. commercialization strategy and changes the reimbursement landscape for Nevisense. For the first time, eligible use of the technology can move from a predominantly cash-pay model into covered care through a major U.S. private insurer, reducing one of the most significant barriers to broader clinical adoption.

SciBase has already established strong commercial momentum in the United States without broad private payer reimbursement. The addition of coverage introduces a new growth driver to an existing business, expanding the number of dermatology practices and patients that can access Nevisense within a reimbursed model.

"This is a defining milestone for SciBase and an important step forward in the development of our U.S. business," said Pia Renaudin, CEO of SciBase. " Highmark coverage begins to remove one of the most important barriers to scale and creates the opportunity to reach a substantially larger portion of the U.S. market. Reimbursement now becomes an additional driver of growth in a business where demand for our technology has already been established."

The United States is SciBase's largest commercial opportunity. Approximately 6,500 to 7,000 private dermatology clinics operate in the U.S., with around 6,000 considered relevant for Nevisense, and an estimated 4 to 4.5 million skin biopsies are performed annually.

The Highmark decision represents more than the addition of a new payer. It begins to address one of the principal constraints on U.S. commercial scale and creates a pathway to convert established clinical adoption into broader reimbursed utilization.

Highmark, together with its Blue-branded affiliates, is one of the largest Blue Cross Blue Shield affiliated organizations in the United States, serving over 7 million members across multiple states.

For dermatologists, reimbursement can reduce the financial barrier to incorporating Nevisense into care for eligible patients while expanding patient access to objective, non-invasive technology that can support the assessment of suspicious skin lesions.

SciBase will continue its engagement across the U.S. payer market while expanding commercial activity in geographies where reimbursement is available.

What the policy covers

Under the policy, Highmark considers EIS medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy.

The procedure is reported with CPT code 0658Tand the key criteria include:

Melanoma is part of the differential diagnosis
The lesion is on the trunk or extremities and measures 2 mm to 20 mm
The patient is 18 or older
The lesion is not on a mucosal surface, palm, sole or nail, and is not ulcerated, bleeding or recently traumatized
The device is FDA-approved and used by a dermatologist trained in clinical and dermoscopic evaluation of pigmented lesions
The policy applies to all Highmark commercial insured lines of business and to self-funded (ASO) employer groups that elect it. In support of its position, Highmark cites the NCCN Clinical Practice Guidelines for Cutaneous Melanoma (Version 2.2026), which list EIS among technologies that may aid detection of new primary melanoma, and American Academy of Dermatology guidance on emerging noninvasive diagnostics.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 09:00 AM CEST on October 14, 2026.

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com . For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

PR Highmark - eng

Close popup

Left Right

Pioneering detection and prediction in dermatology

Our Company

Quick Links

Signup for alerts

Stay in touch

Footer

Original on investors.scibase.se

2026-10-09 SciBase's rights issue registered, conversion of BTA into shares Bull 0 Bear 0 Routine

Oct 09 2026

SciBase Holding AB (publ) ("SciBase" or the "Company") announces that the rights issue of shares of approximately SEK 57.5 million resolved by the Board of Directors on 3 September 2026, the outcome of which was announced on 1 October 2026 (the "Rights Issue"), has been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed shares ("BTA") on Nasdaq First North Growth Market is Friday 16 October 2026. The record date with Euroclear Nordics AB for the conversion of BTA into shares is Tuesday 20 October 2026, and the new shares are expected to be available in the respective securities accounts and custody accounts on Thursday 22 October 2026.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

Conversion of BTA into shares

The Rights Issue was registered with the Swedish Companies Registration Office on 8 October 2026. Through the Rights Issue, 3,834,487 new shares were issued, and the BTA allotted in the Rights Issue will now be converted into shares. The last day of trading in BTA on Nasdaq First North Growth Market is Friday 16 October 2026. The record date with Euroclear Nordics AB is Tuesday 20 October 2026, and the new shares are expected to be available in the respective securities accounts and custody accounts on Thursday 22 October 2026.

The conversion of BTA into shares takes place automatically and without any specific notification from Euroclear Nordics AB. Holders of nominee-registered holdings will be informed of the conversion in accordance with the procedures of their respective nominee.

Number of shares and share capital

Following the registration of the Rights Issue and the directed set-off issue of 60,000 shares to the guarantor resolved by the Board of Directors on 7 October 2026, the number of shares in SciBase amounts to 14,119,787 shares and the share capital to SEK 70,598,935.

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

Original on investors.scibase.se

2026-10-07 SciBase resolves on a set-off issue of shares to the guarantor in connection with the completed rights issue Bull 0 Bear 0 Routine

Oct 07 2026

SciBase Holding AB (publ) ("SciBase" or the "Company") has today, on 7 October 2026, resolved on a set-off issue of 60,000 shares to Bergs Securities AB ("Bergs Securities") in its capacity as guarantor in the Company's recently completed rights issue of shares (the "Rights Issue"), for part of the guarantee compensation, in accordance with the terms of the guarantee commitment announced on 3 September 2026 (the "Compensation Issue"). The resolution by the Board of Directors has been made pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026. The subscription price amounts to SEK 15 per share, corresponding to the subscription price in the Rights Issue, and payment for the shares has been made by way of set-off against the part of Bergs Securities' claim, amounting to SEK 0.9 million, for guarantee compensation that they elected to receive in the form of new shares. All shares in the Compensation Issue have been subscribed for and allotted.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

Background

On 3 September 2026, the Board of Directors of SciBase resolved on the Rights Issue, the outcome of which was announced on 1 October 2026. In connection with the Rights Issue, Bergs Securities provided a guarantee commitment of approximately SEK 24.2 million. For the guarantee commitment, guarantee compensation is payable amounting to 10 percent of the guaranteed amount in cash or, alternatively, 12 percent of the guaranteed amount in newly issued shares in the Company at a subscription price corresponding to the subscription price in the Rights Issue. The guarantee compensation shall, according to the guarantee agreement, be paid in full or in part in either form.

Bergs Securities has notified the Company that it wishes to receive part of the guarantee compensation, totalling SEK 0.9 million, in the form of newly issued shares.

The Compensation Issue

In order to fulfil the Company's contractual obligation towards the guarantor, the Board of Directors has today, pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026, resolved on the Compensation Issue. The subscription price amounts to SEK 15 per share, which corresponds to the subscription price in the Rights Issue. Payment for the shares is made by way of set-off against part of Bergs Securities' claim for guarantee compensation of SEK 0.9 million. All shares in the Compensation Issue have been subscribed for and allotted.

Reasons for the deviation from the shareholders' preferential rights

The reason for the deviation from the shareholders' preferential rights is to fulfil the Company's obligation towards Bergs Securities under the guarantee agreement entered into in connection with the Rights Issue. The Board of Directors considers it to be in the interest of the Company and its shareholders that part of the guarantee compensation is paid in the form of newly issued shares rather than in cash, as the Company thereby retains cash that can be used in its operations. The terms of the guarantee compensation, including the possibility to receive the compensation in newly issued shares and the maximum number of shares that could be issued, were announced in connection with the resolution on the Rights Issue on 3 September 2026.

The subscription price in the Compensation Issue was determined through arm's length negotiations between the Company and Bergs Securities when the letter of intent regarding the guarantee commitment was entered into, and corresponds to the subscription price in the Rights Issue. Against this background, the Board of Directors considers the subscription price to be on market terms.

Number of shares, share capital and dilution

Through the Compensation Issue, the number of shares in SciBase increases by 60,000 shares, from 14,059,787 shares to 14,119,787 shares, and the share capital increases by SEK 300,000, from SEK 70,298,935 to SEK 70,598,935, calculated following registration of the Rights Issue with the Swedish Companies Registration Office. The Compensation Issue entails a dilution of approximately 0.4 percent of the number of shares and votes in the Company.

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

Original on investors.scibase.se

2026-10-07 Recalculation of warrants of series TO 2 following rights issue Bull 0 Bear 0 Routine

Oct 07 2026

In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of shares that the board of directors resolved upon on September 3, 2026 (the "Rights Issue").

Following the completed recalculation, SciBase can announce that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share has changed in accordance with the following. Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 shares at a subscription price of SEK 37.47 per share.

Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 new shares in the Company during the period from and including on 3 April 2029, until and including 17 April 2029.

The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.

For additional information, please contact:

Michael Colérus, CEO, tel. +46703413472, e-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, on October 7, 2026 at 08.00 CET.

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com . For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

SciBase - PR - recalculation TO 2 - final Oct

Close popup

Left Right

Pioneering detection and prediction in dermatology

Our Company

Quick Links

Signup for alerts

Stay in touch

Footer

Original on investors.scibase.se

2026-10-01 SciBase announces outcome of rights issue of shares Bull 0 Bear 4 Financing

Oct 01 2026

SciBase Holding AB (publ) ("SciBase" or the "Company") today, on 1 October 2026, announces the outcome of the rights issue of shares of approximately SEK 57.5 million resolved by the Board of Directors on 3 September 2026 pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026 (the "Rights Issue"). The subscription period ended on 29 September 2026. The outcome shows that 2,681,085 shares, corresponding to approximately SEK 40.2 million or approximately 69.9 percent of the Rights Issue, were subscribed for with the support of subscription rights, and that 133,116 shares, corresponding to approximately SEK 2.0 million or approximately 3.5 percent of the Rights Issue, were subscribed for without the support of subscription rights. In total, 2,814,201 shares were thus subscribed for with and without the support of subscription rights, corresponding to approximately SEK 42.2 million or approximately 73.4 percent of the Rights Issue. The remaining 1,020,286 shares, up to full subscription of the Rights Issue, corresponding to approximately SEK 15.3 million or approximately 26.6 percent of the Rights Issue, are allotted to Bergs Securities AB ("Bergs Securities") in accordance with the guarantee commitment entered into. The Rights Issue is thereby fully subscribed and SciBase will receive approximately SEK 57.5 million before deduction of issue costs, enabling the Company's continued commercialisation with a focus on the US market.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

"We are very grateful for the confidence that shareholders and new investors have shown in us. The raised capital enables the Company to continue to build its position in melanoma diagnostics in the United States, where SciBase is approaching an important milestone in the form of reimbursement, and to take the next step in the collaboration with Castle Biosciences", says Pia Renaudin, CEO of SciBase.

"The broad support from our shareholders is a sign of strength. With strengthened finances and an organisation that is performing well in both the United States and Germany, SciBase is well equipped for the next phase and the upcoming CEO transition", says Jesper Høiland, Chairman of the Board of SciBase.

Outcome of the Rights Issue

The subscription period in the Rights Issue ran from and including 15 September 2026 up to and including 29 September 2026. The outcome shows that 2,681,085 shares were subscribed for with the support of subscription rights, corresponding to approximately SEK 40.2 million or approximately 69.9 percent of the Rights Issue. In addition, 133,116 shares were subscribed for without the support of subscription rights, corresponding to approximately SEK 2.0 million or approximately 3.5 percent of the Rights Issue. In total, 2,814,201 shares were thus subscribed for with and without the support of subscription rights, corresponding to approximately SEK 42.2 million or approximately 73.4 percent of the Rights Issue. The remaining 1,020,286 shares, corresponding to approximately SEK 15.3 million and approximately 26.6 percent of the Rights Issue, are allotted to Bergs Securities in accordance with the guarantee commitment entered into. The Rights Issue is thereby fully subscribed.

The subscription price in the Rights Issue was SEK 15 per share. Through the Rights Issue, SciBase will receive approximately SEK 57.5 million before deduction of issue costs, which are estimated to amount to approximately SEK 4.8 million (including any cash guarantee compensation, which may amount to a maximum of approximately SEK 2.4 million). The net proceeds enable continued commercialisation activities with a focus on the US market.

Notification of allotment

Allotment of shares subscribed for without the support of subscription rights has been made in accordance with the allotment principles set out in the information document published by the Company on 14 September 2026. Notification of allotment will be made through the distribution of contract notes. Subscribed and allotted shares shall be paid for in cash in accordance with the instructions on the contract note. Investors who subscribed through a nominee will receive notification of allotment in accordance with the procedures of their respective nominee. Only those who have been allotted shares will be notified.

Trading in BTA and new shares

Trading in BTA (paid subscribed shares) will continue on Nasdaq First North Growth Market until the Rights Issue has been registered with the Swedish Companies Registration Office. The last day of trading in BTA is expected to be on or around 16 October 2026, after which BTA will be converted into shares without specific notification from Euroclear Nordics AB.

Compensation to the guarantor

In connection with the Rights Issue, Bergs Securities has provided a guarantee commitment of approximately SEK 24.2 million. For the guarantee commitment, guarantee compensation is payable amounting to 10 percent of the guaranteed amount in cash or, alternatively, 12 percent of the guaranteed amount in newly issued shares in the Company. The subscription price for shares issued as guarantee compensation shall be set at SEK 15 per share, corresponding to the subscription price in the Rights Issue.

Bergs Securities shall, no later than five (5) banking days after the end of the subscription period, notify the Company of the extent to which the guarantee compensation is to be paid in cash and in the form of newly issued shares, respectively. The guarantee compensation may be paid in full or in part in either form. Any resolution on a directed issue of shares as guarantee compensation will be announced through a separate press release.

Number of shares, share capital and dilution

Through the Rights Issue, the number of shares in SciBase increases by 3,834,487 shares, from 10,225,300 shares to 14,059,787 shares, and the share capital increases by SEK 19,172,435, from SEK 51,126,500 to SEK 70,298,935, corresponding to a dilution of approximately 27 percent of the total number of shares and votes in the Company following registration of the new shares with the Swedish Companies Registration Office.

Should the guarantee compensation be paid in full in the form of newly issued shares, the number of shares will increase by a further maximum of 193,669 shares and the share capital by a maximum of SEK 968,345, corresponding to an additional dilution of approximately 1.4 percent.

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

Original on investors.scibase.se

2026-09-25 SciBase announces confirmed guarantee commitment in connection with ongoing rights issue Bull 0 Bear 0 Financing

Sep 25 2026

SciBase Holding AB (publ) ("SciBase" or the "Company") announces that Bergs Securities AB ("Bergs Securities") has today, on 25 September 2026, fulfilled the letter of intent to provide a guarantee commitment (the "Guarantee Intention") announced by SciBase on 3 September 2026 in connection with the Company's ongoing rights issue of shares of approximately SEK 57.5 million (the "Rights Issue"). The fulfilment of the Guarantee Intention means that Bergs Securities has provided a binding guarantee commitment of approximately SEK 24.2 million, corresponding to approximately 42 percent of the Rights Issue (the "Guarantee Commitment"). Together with the subscription undertakings previously entered into, amounting to approximately SEK 33.3 million and corresponding to approximately 58 percent of the Rights Issue, the Rights Issue is thus covered to 100 percent by subscription undertakings and the guarantee commitment.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

Subscription undertakings and the Guarantee Commitment

Under the Guarantee Intention, which was entered into in connection with the Board of Directors' resolution on the Rights Issue on 3 September 2026, Bergs Securities could, up until the expiry of the subscription period in the Rights Issue, fulfil the Guarantee Intention by delivering a guarantee confirmation, whereupon a binding guarantee commitment arises. SciBase has today, on 25 September 2026, received such guarantee confirmation from Bergs Securities.

The Guarantee Commitment means that Bergs Securities has undertaken to subscribe for shares in the Rights Issue that are not subscribed for with or without the support of subscription rights, up to an amount of approximately SEK 24.2 million. Allotment will be made in accordance with the allotment principles announced on 3 September 2026. In support of the Guarantee Commitment, Bergs Securities has entered into sub-guarantee agreements with a consortium of investors corresponding to the entire Guarantee Commitment.

The guarantee compensation and the other terms of the Guarantee Commitment are unchanged from those set out in the press release published by the Company on 3 September 2026.

Several existing shareholders, including Ribbskottet AB, Castle Biosciences Inc, Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Praktikerinvest AB, as well as members of the Company's Board of Directors and management, have previously entered into subscription undertakings in an aggregate amount of approximately SEK 33.3 million, corresponding to approximately 58 percent of the Rights Issue. No compensation is payable for the subscription undertakings.

The subscription undertakings and the Guarantee Commitment amount in aggregate to approximately SEK 57.5 million, corresponding to 100 percent of the Rights Issue. Neither the subscription undertakings nor the Guarantee Commitment are secured by bank guarantee, blocked funds, pledge or similar arrangements.

The Rights Issue in brief

The subscription price is SEK 15 per share. Shareholders who were registered in the share register maintained by Euroclear Nordics AB on the record date of 10 September 2026 received one (1) subscription right for each share held. Eight (8) subscription rights entitle the holder to subscribe for three (3) new shares.
The subscription period runs from and including 15 September 2026 up to and including 29 September 2026.
Trading in subscription rights on Nasdaq First North Growth Market took place up to and including 24 September 2026.
Trading in BTA (paid subscribed shares) on Nasdaq First North Growth Market continues until on or around 16 October 2026.
The outcome of the Rights Issue is expected to be announced on or around 1 October 2026.
An information document relating to the Rights Issue is available on the Company's website, https://investors.scibase.se.

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

Original on investors.scibase.se

2026-09-15 Updated first day of trading in subscription rights and paid-up subscribed shares Bull 0 Bear 0 Routine

Sep 15 2026

SciBase Holding AB (publ) ("SciBase" or the "Company") today announces that the Company has resolved to update the first day of trading in subscription rights and paid subscribed shares ("BTA") on Nasdaq First North Growth Market in the Company's ongoing rights issue of shares (the "Rights Issue"). According to the preliminary timetable, the first day of trading in subscription rights and BTAs was to be 15 September 2026. Under the updated timetable, the first day of trading in subscription rights and BTAs will be 16 September 2026.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

The subscription period in the Rights Issue remains unchanged and runs from 15 September 2026 up to and including 29 September 2026.

Updated timetable for the Rights Issue


Subscription period	15-29 September 2026
Trading in subscription rights	16-24 September 2026
Trading in paid subscribed shares (BTA)	16 September - 16 October 2026
Expected announcement of the outcome of the Rights Issue	1 October 2026

Original on investors.scibase.se

2026-09-14 SciBase publishes information document regarding the rights issue Bull 0 Bear 0 Routine

Sep 14 2026

The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") is publishing an information document in connection with the rights issue of shares of approximately SEK 58 million (the "Rights Issue"), which the Company's Board of Directors resolved upon on 3 September 2026. The information document is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website at https://www.bergssecurities.se/ .

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

In connection with the Rights Issue, the Company has prepared an information document (the "Information Document"). The Information Document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Nor does the Information Document constitute an exemption document in the form prescribed in accordance with the requirements of Annex IX to Article 1(4)(db) of the Prospectus Regulation.

SciBase today announces that the Information Document has been published and is available on the Company's website, http://www.scibase.com/ , and will also be available on Bergs Securities' website, https://www.bergssecurities.se/ .

Subscription forms will be available on the Company's website and will also be available on Bergs Securities' website, https://www.bergssecurities.se/ .

Indicative timetable for the Rights Issue


Trading in subscription rights	15-24 September 2026
Subscription period	15-29 September 2026
Trading in paid subscribed shares (BTA)	15 September - 16 October 2026
Expected publication of the outcome of the Rights Issue	1 October 2026

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

Original on investors.scibase.se

2026-09-08 SciBase receives additional order from Castle Biosciences, advancing the collaboration Bull 2 Bear 0 Order/contract

Sep 08 2026

SWEDEN - September 8, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.

In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (Nasdaq: CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration project, which aims to predict relapses in atopic dermatitis (AD), is ongoing and this order is for both an acceleration of the initial clinical study as well as preparation for a second clinical study. Deliveries are expected to start in Q4 2026.

"The collaboration with Castle Biosciences is moving forward at a fast pace with rapid patient recruitment in our first joint study and this additional order signals the expansion of our collaboration," said Pia Renaudin, CEO of SciBase. "At SciBase we are very excited to, together with Castle Biosciences, help patients with skin barrier dysfunctions get access to more effective therapies."

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 03:00 PM CEST on September 8, 2026.

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]

About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com . For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

PR order 2 Castle eng

Close popup

Left Right

Pioneering detection and prediction in dermatology

Our Company

Quick Links

Signup for alerts

Stay in touch

Footer